As of 2026-09-20, the EV/EBITDA ratio of Cytosorbents Corp (CTSO) is -3.09. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. CTSO's latest enterprise value is 31.30 mil USD. CTSO's TTM EBITDA according to its financial statements is -10.14 mil USD. Dividing these 2 quantities gives us the above CTSO EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 14.4x - 16.2x | 15.0x |
| Forward P/E multiples | 17.7x - 20.6x | 18.8x |
| Fair Price | (60.01) - (55.21) | (57.20) |
| Upside | -1143.7% - -1060.2% | -1094.8% |
| Date | EV/EBITDA |
| 2026-09-18 | -3.09 |
| 2026-09-17 | -3.09 |
| 2026-09-16 | -3.08 |
| 2026-09-15 | -3.18 |
| 2026-09-14 | -3.19 |
| 2026-09-11 | -3.29 |
| 2026-09-10 | -3.28 |
| 2026-09-09 | -3.27 |
| 2026-09-08 | -3.43 |
| 2026-09-04 | -3.48 |
| 2026-09-03 | -3.48 |
| 2026-09-02 | -3.70 |
| 2026-09-01 | -3.41 |
| 2026-08-31 | -3.42 |
| 2026-08-28 | -3.39 |
| 2026-08-27 | -3.42 |
| 2026-08-26 | -3.54 |
| 2026-08-25 | -3.52 |
| 2026-08-24 | -3.61 |
| 2026-08-21 | -3.61 |
| 2026-08-20 | -3.24 |
| 2026-08-19 | -3.52 |
| 2026-08-18 | -3.54 |
| 2026-08-17 | -3.65 |
| 2026-08-14 | -3.80 |
| 2026-08-13 | -3.56 |
| 2026-08-12 | -3.61 |
| 2026-08-11 | -3.54 |
| 2026-08-10 | -3.56 |
| 2026-08-07 | -3.54 |
| 2026-08-06 | -3.79 |
| 2026-08-05 | -3.70 |
| 2026-08-04 | -3.66 |
| 2026-08-03 | -3.60 |
| 2026-07-31 | -3.55 |
| 2026-07-30 | -3.48 |
| 2026-07-29 | -3.51 |
| 2026-07-28 | -3.61 |
| 2026-07-27 | -3.54 |
| 2026-07-24 | -3.54 |
| 2026-07-23 | -3.55 |
| 2026-07-22 | -3.68 |
| 2026-07-21 | -3.76 |
| 2026-07-20 | -3.67 |
| 2026-07-17 | -3.54 |
| 2026-07-16 | -3.60 |
| 2026-07-15 | -3.73 |
| 2026-07-14 | -3.73 |
| 2026-07-13 | -3.67 |
| 2026-07-10 | -3.68 |